Time to complete:
Date of publication:
In this five minute screencast, we will introduce newer agents that have shown benefits across the cardiorenal metabolic systems including improving outcomes for cardiovascular and renal disease, as well as reducing hospital admissions for heart failure.
For further information on Cardiorenal Metabolic Disease, you can access the Cardio-renal-metabolism Hub for more Modules and Screencasts.
An educational grant was received by Boehringer Ingelheim Ltd for the production of this hub. Editorial and content decisions were made solely by the RCGP